Peroxisome proliferator-activated receptor-γ (PPARγ) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease

Journal of International Medical Research

Volumn 38, Issue 1, 2010, Pages 86-94

  Yu, J ^a   Zhang, Z ^a   Li, Z ^a   Feng, X ^a   He, L ^a   Liu, S ^a   Mao, J ^a   Wang, Guang ^a   Wang, X ^a,b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Coronary artery disease; Coronary flow velocity reserve; Diabetes mellitus; Endothelial function; Peroxisome proliferator activated receptor (PPAR ) agonist; Rosiglitazone

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DIABETIC PATIENT; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC ACTIVATION; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77749301731     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800110     Document Type: Article

References (25)

1. Hadi HA, Al Suwaidi J: Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007; 3: 853-876.
2. Razani B, Chakravarthy MV, Semenkovich CF: Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008; 37: 603-621.
3. Meimoun P, Tribouilloy C: Non-invasive assessment of coronary flow and coronary flow reserve by transthoracic Doppler echocardiography: a magic tool for the real world. Eur J Echocardiogr 2008; 9: 449-457.
4. Martens F-M, Visseren F-L, Lemay J, et al: Metabolic and additional effects of thiazolodinediones. Drugs 2002; 62: 1463-1480.
5. Haffner SM, Greenberg AS, Weston WM, et al: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
6. Majithiya JB, Paramar AN, Balaraman R: Pioglitazone, a PPARγ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 2005; 66: 150-161.
7. Bagi Z, Koller A, Kaley G, et al: PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 2004; 286: H742-H748.
8. Wang G, Wei J, Guan Y, et al: Peroxisome proliferator-activated- γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 2005; 54: 590-597.
9. Yu J, Jin N, Wang G, et al: Peroxisome proliferator-activated receptor γ agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007; 56: 1396-1401.
10. Wang G, Zhang Z, Yu J: Antidiabetic rosiglitazone reduces soluble intercellular adhesion molecule-1 level in type 2 diabetic patients with coronary artery disease. PPAR Res 2008; 2008:548178.
11. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda: National Institutes of Health, 2004 (available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf).
12. Smith SC Jr, Allen J, Blair SN, et al: AHA/ACC Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130-2139.
13. International Diabetes Federation Clinical Guidelines Task Force: Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005 (available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf) .
14. Wang M, Tafuri S: Modulation of PPARγ activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 2003; 89: 38-47.
15. Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
16. Ricote M, Li AC, Willson TM, et al: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
17. Marx N, Schönbeck U, Lazar MA, et al: Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-1103.
18. Ricote M, Huang J, Fajas L, et al: Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 7614-7619.
19. Law RE, Goetze S, Xi XP, et al: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311-1318.
20. Calnek DS, Mazzella L, Roser S, et al: Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57.
21. Szapary PO, Bloedon LT, Samaha FF, et al: Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 182-188.
22. Campia U, Matuskey LA, Panza JA: Perixosome proliferator-activated- γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867-875.
23. Werner C, Kamani CH, Gensch C, et al: The peroxisome proliferator-activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007; 56: 2609-2615.
24. Seki N, Bujo H, Jiang M, et al: A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickening in hypercholesterolemic rabbits. Atherosclerosis 2005; 178: 1-7.
25. Samaha FF, Szapary PO, Iqbal N, et al: Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 624-630.